SE Health

Biogen | October 27, 2016

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m. MT, 11:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation....

Vertex Pharmaceuticals | November 02, 2016

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8th at 3:30 p.m. ET .Management's remarks will be available live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" page. A replay of the conference webcast will be archived on the company's website....

Drug Target Review | January 15, 2020

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Labiotech | January 15, 2020

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...